You can help expand this article with text translated from the corresponding article in French. (August 2015) Click [show] for important translation instructions.
View a machine-translated version of the French article.
Machine translation, like DeepL or Google Translate, is a useful starting point for translations, but translators must revise errors as necessary and confirm that the translation is accurate, rather than simply copy-pasting machine-translated text into the English Wikipedia.
Consider adding a topic to this template: there are already 1,689 articles in the main category, and specifying|topic= will aid in categorization.
Do not translate text that appears unreliable or low-quality. If possible, verify the text with references provided in the foreign-language article.
You must provide copyright attribution in the edit summary accompanying your translation by providing an interlanguage link to the source of your translation. A model attribution edit summary is Content in this edit is translated from the existing French Wikipedia article at [[:fr:bioMérieux]]; see its history for attribution.
You may also add the template {{Translated|fr|bioMérieux}} to the talk page.
bioMérieux SA is a French multinational biotechnology company founded and headquartered in Marcy-l'Étoile, France, close to Lyon. bioMérieux is present in 44 countries and serves more than 160 countries through a large network of distributors.[1]
bioMérieux provides diagnostic solutions (reagents, instruments, software, services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases, cancer screening, and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.[2] bioMérieux is listed on the Euronext Parisstock exchange (BIM – ISIN: FR0013280286).[2]
Revenue
bioMérieux had revenues of €3.1 billion as of 2020 with 93% of sales occurring outside France.[3]
History
In 1897, Marcel Mérieux, former assistant to Louis Pasteur, founded the Mérieux Biological Institute, which later became Institut Mérieux.[4] In 1963, Alain Mérieux founded BD Mérieux, of which he became majority shareholder in 1974. BD Mérieux would later become bioMérieux.[5] The company expanded its services and offerings through product development, acquisitions and partnerships:
Biomedics (Spain) and BTF (Australia), acquired in 2007[9]
AB Biodisk (Sweden), AviaraDx (bioTheragnostics today) (USA) and PML Microbiologicals (USA), acquired in 2008[10]
Meikang Biotech and of Shanghai Zenka Biotechnology, acquired in 2010[11]
AES Laboratoire and Argene (France), acquired in 2011[12]
RAS (India), a specialist in molecular biology, acquired in 2012
Partnership with Quanterix in 2012 for the development of a new generation of ultrasensitive, multiplex immunoassays.[13]
BioFire Diagnostics Inc., a privately held US-based company specialized in molecular biology,[14][15] acquired in 2014
BioMerieux molecular biology affiliate BioFire, LLC. opened the Alain Mérieux Center for Molecular Diagnostics in Salt Lake City, Utah[16] in 2017
Invisible Sentinel, A Philadelphia life sciences company that develops novel technology to quickly detect pathogens in food and beverages including wine and beer.[17]
Institut Mérieux, which belongs to the Mérieux family, is the main shareholder of bioMérieux. Jean-Luc Bélingard is President, and Alexandre Mérieux is General Director.[2] bioMérieux was listed on the stock exchange in 2004.[18]
Labrador Diagnostics filed a lawsuit against BioFire Diagnostics, a subsidiary of bioMérieux, for patent infringement on March 9, 2020.[19] On March 11, 2020, bioMérieux announced the finalization of their real-time PCR SARS-COV-2 R-GENE test. The company also announced the development of a fully automated test based on the BioFire FilmArray technology with the support of the United States Department of Defense. Lastly, bioMérieux launched development on an expanded version of its BioFire FilmArray Respiratory Panel 2. The new version included SARS-CoV-2 in addition to the 21 other common respiratory pathogens and delivered results in approximately 45 minutes.[20][21][22] After this announcement, Labrador issued a statement claiming that when it filed the lawsuit against BioFire it had no idea BioFire was developing COVID-19 testing kits.[23][24]Fortress Investment Group, parent company to Labrador, offered to grant both the defendants and anyone else a royalty-free license for its technology for use in COVID-19 tests.[23] bioMérieux and BioFire declined Labrador's offer.[19]
In June 2021, bioMérieux launched EPISEQ SARS-COV-2, a cloud-based software application for the epidemiological surveillance of SARS-CoV-2 variants. The application identifies variants based on international nomenclatures, including any new variant of concern (VOC), and is compatible with three major sequencing platforms (Illumina, Oxford Nanopore, Thermo Fisher).[25]
